About Midnolin
Midnolin (MIDN) is a protein
from Homo sapiens identified by UniProt accession
Q504T8, 468 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | Midnolin |
|---|
| UniProt accession | Q504T8 |
|---|
| Gene | MIDN |
|---|
| Organism | Homo sapiens |
|---|
| Length | 468 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (70)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.32
- mean corpuscular hemoglobin concentration · score 0.30
- mean corpuscular hemoglobin · score 0.28
- hair color · score 0.24
- erythrocyte count · score 0.23
- total blood protein measurement · score 0.22
- Varicose veins · score 0.21
- red blood cell density measurement · score 0.09
- hepatocellular carcinoma · score 0.07
- cleft palate-lateral synechia syndrome · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q504T8-F1 | alphafold | PREDICTED | 64.95 | — |
Amino-acid sequence (468 residues)
MEPQPGGARS CRRGAPGGAC ELGPAAEAAP MSLAIHSTTG TRYDLAVPPD ETVEGLRKRL SQRLKVPKER LALLHKDTRL SSGKLQEFGV GDGSKLTLVP TVEAGLMSQA SRPEQSVMQA LESLTETQVS DFLSGRSPLT LALRVGDHMM FVQLQLAAQH APLQHRHVLA AAAAAAAARG DPSIASPVSS PCRPVSSAAR VPPVPTSPSP ASPSPITAGS FRSHAASTTC PEQMDCSPTA SSSASPGAST TSTPGASPAP RSRKPGAVIE SFVNHAPGVF SGTFSGTLHP NCQDSSGRPR RDIGTILQIL NDLLSATRHY QGMPPSLAQL RCHAQCSPAS PAPDLAPRTT SCEKLTAAPS ASLLQGQSQI RMCKPPGDRL RQTENRATRC KVERLQLLLQ QKRLRRKARR DARGPYHWSP SRKAGRSDSS SSGGGGSPSE ASGLGLDFED SVWKPEVNPD IKSEFVVA
Explore Midnolin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets